 SYDNEY, Oct. 19, 2021 PRNewswire -- The iQ Group Global Ltd NSX.IQG, on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd LSBD, is pleased to announce that one of its licensees, GBS Inc Nasdaq: GBS; a life sciences company operating in the Asia Pacific region, under license from LSBD, to commercialize its non-invasive, real-time Glucose Salivary test; has filed a Pre-Submission package with the United States US Food and Drug Administration FDA. The purpose of this Pre-Submission is to confirm with the FDA the clinical trial design, including trial objectives. 